Aktienanalyse zu Merit Medical Systems Inc (MMSI)MMSIMerit Medical Systems Inc

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a Q2 revenue of $418.8 million, which is a 9.5% year-over-year increase, and a non-GAAP EPS of $1.19, exceeding expectations by $0.23. Additionally, the forward P/E ratio of 21.88 suggests potential for growth compared to its current price of $90.49. However, the main risk is the current RSI of 55.45, indicating that the stock is nearing overbought territory.

9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.